Balt, a global neurovascular medical device company, has opened its second manufacturing facility in Irvine, California, as part of a multi-year US expansion strategy. The French company plans to invest over $400 million between 2026 and 2030 in manufacturing, infrastructure, research and clinical operations. The expansion is expected to grow Balt's US workforce to approximately 1,200 employees by 2030, up from 450 currently employed in Irvine. The company's Irvine campus is projected to reach 85,000 square feet and serves as a key centre for manufacturing advanced stroke treatment technologies. Founded in 1977, Balt established its US presence in Irvine in 2016 and now operates in over 70 countries. The company specialises in minimally invasive neurovascular devices including stents, catheters and coils used to treat stroke and vascular conditions.

The French medtech company Balt is set to invest $400 million in the United States. Ten years after its arrival across the Atlantic, the group specializing in neurosurgical prostheses continues its American adventure. Neither Donald Trump nor the cost of living in California fazes it. Published on May 18, 2026 at 11:55 Premium Reserved for our Premium subscribers Donald Trump's unpredictability at the White House does not frighten Balt's French CEO. "I've seen different administrations, I haven't seen a fundamental difference," explains CEO Pascal Girin. "As long as you play by their rules, the American market remains the most attractive." Ten years after launching this group specializing in neurosurgical prostheses to conquer the United States, he has just announced his intention to invest an additional $400 million there by 2030. Most of this amount is earmarked for its California plant in Irvine, south of Los Angeles. This content is reserved for Premium and Premium Entreprises subscribers Would you like to read more? Take advantage of our free months or free trials.

DOJ issues first declination under new department-wide CEP in FCPA matter involving medical equipment manufacturer. LinkedIn Facebook X On March 19, 2026, the Department of Justice ("DOJ") announced that it was declining to prosecute Balt SAS, a France-based medical device company, and its subsidiary Balt USA LLC (together, "Balt"), in connection with an alleged foreign bribery scheme involving a physician at a state-owned hospital in France ("Balt declination" or "Balt declination letter"). The Balt declination is the first resolution under Part I of DOJ's recently announced Department-wide Corporate Enforcement Policy ("CEP"). As part of the resolution, Balt has agreed to disgorge approximately $1.2 million in profits tied to the misconduct. Balt also entered into a parallel resolution with French authorities, which, per the DOJ declination letter, "will include corporate compliance requirements imposed under the French system." As set forth in the Balt declination letter, between approximately 2017 and 2023, Balt paid more than $600,000 in bribes to an employee of a French state-owned hospital to secure purchases of Balt medical devices. The payments were funneled through a third-party consultant in Belgium and were disguised as consulting fees and bonuses. Balt sought to conceal the scheme through the use of sham consulting agreements, fake invoices, and personal email accounts. The scheme generated approximately $1.68 million in revenue and roughly $1.21 million in profits for Balt. DOJ found that Balt qualified for a declination under Part I of the CEP because it made a timely and voluntary self-disclosure to the Fraud Section, fully and proactively cooperated with the government's investigation, timely and appropriately remediated, and lacked aggravating circumstances that "when weighed against Balt's voluntary self-disclosure, cooperation, and remediation, would warrant a disposition other than a resolution under Part I of the CEP." DOJ specifically cited Balt's "accept[ance of] responsibility for the criminal conduct," its agreement to continue cooperating with ongoing investigations and prosecutions, and its agreement to disgorge ill-gotten gains. In addition, DOJ highlighted Balt's remediation efforts, including disciplining the individuals involved, ending the business relationships that gave rise to the misconduct, providing compliance training for senior management, and strengthening its compliance program and internal controls. In many ways, the Balt declination does not appear to mark a new approach to corporate resolutions. Indeed, DOJ relied on the same core factors it emphasized in prior declinations (i.e., timely self-disclosure, full cooperation, appropriate remediation, no aggravating circumstances, and disgorgement of profits tied to the misconduct), which makes sense given how closely the new Department-wide CEP aligns with the framework that was previously in place under the Criminal Division's CEP. Even so, the Balt matter is significant as the first example of how DOJ intends to apply the Department-wide policy in practice. The resolution suggests that when a company satisfies the standards set out in Part I of the CEP, DOJ will offer a declination as it has promised. The resolution also reinforces a message DOJ has continued to emphasize: its desire to hold individuals accountable for misconduct. On March 4, 2026, a few weeks prior to the Balt declination, a federal grand jury indicted David Ferrera, a senior executive of Balt USA LLC, and Marc Tilman, a Belgium-based consultant, in connection with the bribery scheme at issue in the Balt declination, charging them with conspiracy to violate the FCPA, substantive FCPA violations, conspiracy to commit money laundering, and money laundering. In line with DOJ's practice historically to decline to protect individuals as part of a corporate resolution, the Balt declination letter expressly states that it "does not provide any protection against prosecution of any individuals, regardless of their affiliation with Balt." Furthermore, in announcing the resolution, Assistant Attorney General A. Tysen Duva emphasized that DOJ's resolution "credits Balt's self-report to the Department as well as its full cooperation and timely remediation" and that the indictment against Ferrera and Tilman "demonstrates the Criminal Division's unwavering pursuit of culpable individuals that engage in corrupt conduct." Key Takeaways Balt is the first company to receive a public declination under DOJ's new Department-wide CEP, but the outcome is broadly consistent with DOJ's previous approach under the Criminal Division's CEP. This resolution reinforces the importance of having strong internal compliance systems, reporting channels, and prompt internal investigation procedures in place. At the same time, companies should not view self-disclosure as automatic or risk-free. Those decisions remain highly fact-specific and should be made carefully and with counsel. Finally, DOJ again made clear that leniency for a company does not mean leniency for the individuals involved. Even where a company meets DOJ's standards for a declination, employees, executives, and agents tied to the misconduct still may face investigation and prosecution. DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising. (C) Cadwalader, Wickersham & Taft LLP 2026